REGULATION OF GENETIC ASSET-BACKED SECURITIES: LEGAL, FINANCIAL AND ETHICAL FRAMEWORK

1. INTRODUCTION

Genetic asset-backed securities refer to proposed or emerging financial arrangements in which financial instruments derive their value from rights, contractual revenues, intellectual property, licensing income or other legally recognized economic interests associated with genetic resources, genomic research, biotechnology inventions or genetic-data-related commercial activities.

Such arrangements may involve royalty streams from patented genetic technologies, licensing revenues from biotechnology research, commercial rights associated with genetic databases, or securitization of revenues generated by genetic diagnostic and pharmaceutical innovations.

The concept raises significant legal and ethical concerns because genetic information is closely connected with human identity, privacy, bodily autonomy and collective biological heritage. Unlike conventional financial assets, genetic information may involve individuals, families, indigenous communities and future generations.

Consequently, genetic information cannot automatically be treated as transferable commercial property or an asset available for unrestricted securitization. Financial institutions must distinguish between legally transferable economic rights and personal genetic information or biological materials subject to consent, privacy and regulatory restrictions.

In India, regulation requires consideration of securities law, intellectual property law, data protection, biodiversity legislation, biomedical research ethics and contractual obligations.

2. LEGAL FRAMEWORK GOVERNING GENETIC ASSET-BACKED SECURITIES IN INDIA

A. SECURITIES CONTRACTS (REGULATION) ACT, 1956

The Act provides the statutory foundation for regulating securities transactions in India. Whether a genetic asset-backed financial arrangement falls within securities regulation depends on its legal structure and the nature of the instrument issued.

B. SEBI ACT, 1992

The Securities and Exchange Board of India regulates securities markets, investor protection and relevant market intermediaries. Where a genetic asset-backed instrument constitutes a regulated security or investment product, applicable SEBI requirements must be examined.

C. COMPANIES ACT, 2013

Companies issuing financial instruments linked to biotechnology assets must comply with applicable provisions concerning securities issuance, disclosure, corporate governance and investor protection.

D. DIGITAL PERSONAL DATA PROTECTION ACT, 2023

Genetic information relating to identifiable individuals may constitute personal data. Its processing must comply with applicable data protection obligations, including lawful processing, consent requirements where applicable, security safeguards and restrictions on unauthorized disclosure.

E. BIOLOGICAL DIVERSITY ACT, 2002

The Biological Diversity Act, as amended in 2023, regulates access to biological resources and associated traditional knowledge under its applicable framework. Commercial arrangements involving biological resources must consider statutory access, benefit-sharing and approval requirements.

F. PATENTS ACT, 1970

Biotechnology inventions may generate intellectual property rights capable of supporting commercial licensing arrangements. However, naturally occurring genetic material and discoveries concerning living organisms must be evaluated under the Act's patentability restrictions, including Section 3.

G. TRANSPLANTATION OF HUMAN ORGANS AND TISSUES ACT, 1994

Where financial arrangements involve human organs or tissues, the prohibition on commercial dealings in human organs and applicable transplantation safeguards become relevant. Such biological materials cannot simply be converted into ordinary financial commodities.

3. PRINCIPAL REGULATORY REQUIREMENTS

A. LEGAL IDENTIFICATION OF THE UNDERLYING ASSET

The issuer must identify precisely what generates the financial value. Potential underlying interests include:

Biotechnology patent royalties.

Contractual licensing revenues.

Commercial research agreements.

Legally transferable intellectual property rights.

Revenue streams from genetic diagnostic technologies.

Lawfully commercialized biotechnology products.

Personal genetic identity, biological autonomy and confidential medical information should not be confused with transferable financial property.

B. SECURITIES ISSUANCE AND DISCLOSURE

Where the instrument qualifies as a regulated security, issuers must satisfy applicable registration, disclosure, offer-document and investor-protection requirements.

Investors should receive accurate information concerning ownership, intellectual property validity, revenue projections, regulatory approvals, commercial risks and potential litigation.

C. DATA PRIVACY AND GENETIC CONFIDENTIALITY

Financial institutions must not assume that purchasing a revenue-generating asset provides unrestricted access to the underlying genetic information.

Identifiable genetic data must remain subject to applicable privacy, confidentiality and lawful-processing requirements.

D. INTELLECTUAL PROPERTY VERIFICATION

Before securitization, issuers should establish that the relevant patents, licences and contractual rights are legally valid, enforceable and transferable.

E. BENEFIT-SHARING OBLIGATIONS

Where biological resources or associated traditional knowledge are involved, applicable biodiversity access and benefit-sharing requirements must be respected.

F. ETHICAL INVESTOR PROTECTION

Financial arrangements must not depend upon unauthorized commercialization of human biological materials, exploitation of research participants or misleading representations about ownership of genetic information.

4. MAJOR ETHICAL AND LEGAL CHALLENGES

COMMODIFICATION OF HUMAN GENETIC INFORMATION: Treating personal genetic information as an ordinary financial commodity may undermine privacy, dignity and individual autonomy.

UNCERTAIN OWNERSHIP RIGHTS: Genetic information may involve individuals, research institutions, laboratories and collective biological interests. These interests do not automatically establish unrestricted ownership rights.

INFORMED CONSENT: Consent for medical research or genetic testing does not necessarily authorize subsequent commercial securitization or unrelated financial exploitation.

BIOLOGICAL RESOURCE EXPLOITATION: Commercial use of biological resources without satisfying applicable access and benefit-sharing requirements may create legal disputes.

FINANCIAL MISREPRESENTATION: Inflated patent valuations, uncertain licensing revenues and exaggerated claims about genetic databases may mislead investors.

INTERGENERATIONAL PRIVACY: Genetic information may reveal information about biological relatives who have not independently consented to its disclosure.

MARKET SPECULATION: Speculative trading based on uncertain genetic research outcomes may expose investors and research participants to significant financial and ethical risks.

5. IMPORTANT JUDICIAL DECISIONS

There is no established Indian judicial precedent specifically regulating genetic asset-backed securities. However, the following decisions provide relevant principles concerning genetic privacy, intellectual property, securities regulation, biological-resource commercialization and informed consent.

1. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017) 10 SCC 1 – Analogous authority

The Supreme Court recognized privacy as a fundamental right under Article 21. The judgment emphasized informational privacy, individual autonomy and dignity. These principles are relevant when genetic information is used in commercial financial arrangements. Securitization must not become a mechanism for unauthorized exploitation of identifiable genetic information.

2. Divya Pharmacy v. Union of India (2018) – Directly relevant biodiversity authority

The Uttarakhand High Court examined benefit-sharing obligations under the Biological Diversity Act, 2002. The decision is important for commercial arrangements involving biological resources and associated traditional knowledge. It supports the principle that commercial exploitation of biological resources must respect applicable statutory benefit-sharing requirements.

3. Novartis AG v. Union of India (2013) 6 SCC 1 – Direct biotechnology intellectual property relevance

The Supreme Court examined pharmaceutical patentability under Section 3(d) of the Patents Act, 1970. The judgment is relevant to the valuation of biotechnology-related intellectual property because financial instruments based on patent royalties must rely on legally patentable and enforceable inventions.

4. Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2019) 3 SCC 381 – Direct biotechnology intellectual property relevance

The Supreme Court considered disputes concerning genetically modified seeds and patent protection. The judgment illustrates the legal complexity of biotechnology intellectual property and the importance of establishing valid proprietary rights before commercial exploitation.

5. Sahara India Real Estate Corporation Ltd. v. SEBI (2013) 1 SCC 1 – Direct securities regulatory authority

The Supreme Court examined the regulatory treatment of securities offerings and investor protection. The judgment reinforces that financial instruments cannot escape securities regulation merely because their commercial structure is presented as a private investment arrangement. This principle is important when determining whether genetic asset-backed instruments require SEBI compliance.

6. N. Narayanan v. Adjudicating Officer, SEBI (2013) 12 SCC 152 – Direct securities disclosure authority

The Supreme Court emphasized corporate accountability, accurate disclosure and transparency in securities markets. Issuers of genetic asset-backed instruments must provide reliable information about underlying intellectual property, commercial revenues, regulatory risks and financial liabilities.

7. Samira Kohli v. Dr. Prabha Manchanda (2008) 2 SCC 1 – Analogous informed-consent authority

The Supreme Court explained the requirements of valid medical consent. Consent for genetic testing or biomedical research should not automatically be interpreted as consent to unrelated commercial exploitation or financial securitization of associated personal information.

6. REGULATORY RESPONSIBILITIES OF FINANCIAL AND BIOTECHNOLOGY INSTITUTIONS

Financial institutions, biotechnology companies, research organizations and investment intermediaries should establish appropriate compliance mechanisms.

Important responsibilities include:

Verify the legal ownership and transferability of underlying intellectual property.

Determine whether the financial instrument qualifies as a security under applicable legislation.

Comply with relevant SEBI regulations and securities disclosure requirements.

Obtain appropriate permissions for commercial access to regulated biological resources.

Respect applicable benefit-sharing obligations.

Ensure that personal genetic information is not treated as unrestricted commercial collateral.

Verify research-participant consent and contractual commercialization rights.

Conduct independent valuation of biotechnology-related intellectual property.

Disclose patent disputes, licensing restrictions and regulatory uncertainties.

Maintain confidentiality and cybersecurity safeguards.

Establish mechanisms for addressing investor complaints and financial misrepresentation.

7. LEGAL CONSEQUENCES OF NON-COMPLIANCE

Non-compliance may result in:

Regulatory investigation and financial penalties under applicable securities legislation.

Suspension or cancellation of relevant regulatory permissions.

Civil liability arising from contractual breaches or misrepresentation.

Intellectual property infringement proceedings.

Enforcement action for violations of biodiversity access and benefit-sharing requirements.

Liability for unlawful processing or disclosure of personal data.

Investor compensation claims where legally established.

Criminal consequences where the conduct satisfies applicable statutory offences.

The precise consequences depend on the legal structure of the financial instrument, the underlying asset and the applicable statutory provisions.

8. FUTURE REGULATORY DEVELOPMENTS

As biotechnology commercialization expands, India may require more specific regulatory guidance addressing financial products linked to genetic research and biological resources.

Potential reforms include:

Clear classification standards for biotechnology-linked financial instruments.

Specific disclosure requirements for genetic intellectual property valuations.

Stronger safeguards against unauthorized commercialization of personal genetic information.

Greater transparency concerning research-participant benefit-sharing.

Standardized procedures for verifying patent and licensing rights.

Independent ethical assessments of financial arrangements involving human biological materials.

Coordination between SEBI, DGFT, biodiversity authorities and data protection institutions where their respective jurisdictions are engaged.

Such reforms should distinguish between legitimate securitization of commercial revenues and impermissible commodification of human biological identity.

9. CONCLUSION

Genetic asset-backed securities represent a complex intersection of biotechnology, intellectual property, financial markets, data protection and bioethics. Although legally transferable patent rights, licensing revenues and contractual commercial interests may potentially support financial arrangements, personal genetic information and human biological materials cannot automatically be treated as unrestricted financial assets.

India's securities legislation, Patents Act, Biological Diversity Act, data protection framework and constitutional privacy principles provide important regulatory safeguards. Judicial decisions such as Puttaswamy, Divya Pharmacy, Novartis and Sahara India Real Estate Corporation establish relevant foundations for privacy, benefit-sharing, intellectual property protection and investor transparency.

Ultimately, responsible regulation must balance biotechnology investment and commercial innovation with human dignity, genetic privacy, equitable benefit-sharing and investor protection. Financial innovation should support legitimate biotechnology development without converting personal genetic identity or vulnerable biological resources into instruments of exploitation.